AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)Business Wire · 2 days ago
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative NeoplasmsBusiness Wire · 4 days ago
AN2 Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire · 5 days ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)PRNewsWire · Oct 12, 2026
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKBusiness Wire · Sep 28, 2026
AN2 Therapeutics: A Failed Drug Could Become A Major Value DriverSeeking Alpha · Sep 22, 2026AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.24 | -$0.18 | Beat |
| May 11, 2026 | -$0.23 | -$0.29 | Miss |
| Mar 17, 2026 | -$0.24 | -$0.29 | Miss |
| Nov 12, 2025 | -$0.23 | -$0.31 | Miss |
| Aug 12, 2025 | -$0.31 | -$0.21 | Beat |
| May 13, 2025 | -$0.26 | -$0.35 | Miss |